Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging Phase 2 study of BMS-936558 (MDX-1106) in advanced/metastatic clear-cell renal cell carcinoma after anti-angiogenic therapy
2011-002957-67Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nivolumab in clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival (primary, dose–response). Started Oct 2011; status: completed.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2011-002957-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002957-67.